Oncolytic Virus Treatment for Glioblastoma Recorded Session
This course provides an overview of the research specific to the role Zika virus may play in relation to the treatment of glioblastoma (GBM).
If you attended Oncolytic Virus Treatment for Glioblastoma on June 23, 2022, you will not be able to claim credit again for this course. However, you are welcome to still watch the content.
Target Audience
This course is intended for all physicians including generalists, neurologists, intensivists, radiologists, and pathologists, RN's, PA's, NP's, RTT's, and various other members of the health care team
Learning Objectives
At the end of this session, learners should be able to:
- Ability to provide clinical background on GBM
- Identifying the reasons these tumors are resistant to treatment
- Defining the role oncolytic viruses play in treating GBM
- Reviewing early data on the research related to Zika virus in this treatment
Faculty
Richard A Rovin, MD; Advocate Aurora Health
Eric Maas, MD; Advocate Aurora Health
Paul Vilar, MSN, RN, SCRN; Advocate Aurora Health
Rachael Wade, MHA; Advocate Aurora Health
Amy Campbell, Executive Assistant; Advocate Aurora Health
Disclosure
The following faculty speakers and/or planning committee members have disclosed the following:
Faculty Name | Name of Ineligible Companies | Nature of Relationship |
Richard A. Rovin, MD | UP Oncolytics, Inc | Co-Founder |
The other planner(s) and speaker(s) have indicated that there are no relevant financial relationships with any ineligible companies to disclose. Conflict of interest have been identified and mitigated prior to the activity.
Accreditation Statement
In support of improving patient care, Advocate Aurora Health is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Credit Statement(s)
American Medical Association (AMA)
Advocate Aurora Health designates this enduring activity for a maximum of 1.00 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Available Credit
- 1.00 AMA PRA Category 1 Credit™Aurora Health Care is accredited by the Wisconsin Medical Society to provide continuing medical education for physicians. Aurora Health Care designates this activity for a maximum of 1.00 AMA PRA Category 1 Credit(s)TM. Physicians should only claim credit commensurate with the extent of their participation in the activity.
- 1.00 AttendanceAttendance Credit
- 1.00 Approved AMA PRA Category 1 Credit™
Price
If you attended Oncolytic Virus Treatment for Glioblastoma on June 23, 2022, you will not be able to claim credit again for this course. However, you are welcome to still watch the content.
Click “Take Course” to register for this program.
Contact the Advocate Aurora Health CME Office at cme@aah.org if you have any questions or need assistance.